Pharmacokinetics and Pharmacodynamics of Sugammadex Dosed by Corrected Body Weight for Reversal of Vecuronium in Obese Patients

Abstract Background Dosing in obese individuals is complicated by obesity-related pathophysiological changes and deserves further investigation. Objective This study aimed to find out the influence of obesity on pharmacokinetics (PK) and pharmacodynamics (PD) of sugammadex dosed by corrected body weight (CBW) with different body mass index (BMI). Methods This prospective observational cohort study included 48 patients, who were divided into non-obese, obese, and morbidly obese groups ( n = 16 per group). At the end of laparoscopic surgical procedures, each patient received 2 mg/kg sugammadex dosed by CBW to reverse vecuronium-induced moderate neuromuscular blockade (NMB) monitored by train-of-four (TOF) setting a primary efficacy of TOF ratio to ≥ 0.9. Blood samples were collected at 2, 3, 5, 10, 15, 20, 30, 60, 120, 240, 360 and 480 min after administering sugammadex. Finally, concentration of sugammadex was identified using ultra-high-performance liquid chromatography-tandem mass spectrometry (UHPLC-MS) and PK parameters of sugammadex were calculated using Phoenix WinNonLin software. Results PK and PD data were obtained from 48 patients. C max , T max , t 1/2β , AUC 0−t , and AUC 0−∞ were significantly different between non-obese and the other two groups ( P < 0.05), whereas V d and CL showed no significant differences among three groups ( P > 0.05). Moreover, the average times to recover from moderate NMB in non-obese, obese and morbidly obese groups were 178 ± 7.52 s, 200 ± 13.2 s and 226 ± 19.9 s respectively and did not significantly differ among three groups ( P > 0.05). Conclusion This study served as supplement to PK and PD of sugammadex in patients with different BMI and demonstrated sugammadex of 2 mg/kg dosed by CBW efficiently reversed vecuronium-induced moderate NMB in obese or morbidly obese patients although some of PK parameters changed with different BMI. Trial Registration: The study was registered prior to patient enrollment at clinicaltrials.gov (NCT05328778; principal investigator: Bo Xu; first submitted on 4 March 2022).

Authors

Institutions

Publication Details

Journal
Research Square
Published
2026-11-12
DOI
https://doi.org/10.21203/rs.3.rs-11068106/v1
Primary Topic
Anesthesia and Sedative Agents
Type
preprint

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Pharmacokinetics and Pharmacodynamics of Sugammadex Dosed by Corrected Body Weight for Reversal of Vecuronium in Obese Patients

Weidong Shao, 王寿平, Ming Xiong, Rui Xiao et al.
Research Square
Anesthesia and Sedative Agents
preprint

Pharmacokinetics and Pharmacodynamics of Sugammadex Dosed by Corrected Body Weight for Reversal of Vecuronium in Obese Patients

Weidong Shao, 王寿平, Ming Xiong, Rui Xiao, Wenbin Xi, Nimisha Shawalker, Liangping Wu, Zhihao Lai, Zhonghua Liu, Xiaojiang Dai, Bo Xu
preprint en

Abstract

Abstract Background Dosing in obese individuals is complicated by obesity-related pathophysiological changes and deserves further investigation. Objective This study aimed to find out the influence of obesity on pharmacokinetics (PK) and pharmacodynamics (PD) of sugammadex dosed by corrected body weight (CBW) with different body mass index (BMI). Methods This prospective observational cohort study included 48 patients, who were divided into non-obese, obese, and morbidly obese groups ( n = 16 per group). At the end of laparoscopic surgical procedures, each patient received 2 mg/kg sugammadex dosed by CBW to reverse vecuronium-induced moderate neuromuscular blockade (NMB) monitored by train-of-four (TOF) setting a primary efficacy of TOF ratio to ≥ 0.9. Blood samples were collected at 2, 3, 5, 10, 15, 20, 30, 60, 120, 240, 360 and 480 min after administering sugammadex. Finally, concentration of sugammadex was identified using ultra-high-performance liquid chromatography-tandem mass spectrometry (UHPLC-MS) and PK parameters of sugammadex were calculated using Phoenix WinNonLin software. Results PK and PD data were obtained from 48 patients. C max , T max , t 1/2β , AUC 0−t , and AUC 0−∞ were significantly different between non-obese and the other two groups ( P < 0.05), whereas V d and CL showed no significant differences among three groups ( P > 0.05). Moreover, the average times to recover from moderate NMB in non-obese, obese and morbidly obese groups were 178 ± 7.52 s, 200 ± 13.2 s and 226 ± 19.9 s respectively and did not significantly differ among three groups ( P > 0.05). Conclusion This study served as supplement to PK and PD of sugammadex in patients with different BMI and demonstrated sugammadex of 2 mg/kg dosed by CBW efficiently reversed vecuronium-induced moderate NMB in obese or morbidly obese patients although some of PK parameters changed with different BMI. Trial Registration: The study was registered prior to patient enrollment at clinicaltrials.gov (NCT05328778; principal investigator: Bo Xu; first submitted on 4 March 2022).

Research Square
Guangzhou University of Chinese Medicine (CN), Guangzhou University (CN), Third Affiliated Hospital of Guangzhou Medical University (CN), Southern Command Hospital (IN), Guangdong Provincial Hospital of Traditional Chinese Medicine (CN), Jining Traditional Chinese Medicine Hospital (CN), Rutgers New Jersey Medical School (US), Southern Medical University (CN)
National Natural Science Foundation of China
Good health and well-being
Anesthesia and Sedative Agents
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon